What is known and Objective Aflibercept, a recombinant protein designed to suppress the
vascular endothelial growth factor (VEGF) signalling pathway, has been used in patients …

Background and objective Aflibercept; a decoy receptor for vascular endothelial growth
factors (VEGFs) and placental growth factor (PLGF), in combination with FOLFIRI (leucovorin …

Background: Metastatic colorectal cancer (mCRC) represents a substantial health burden
globally and an increasing challenge in Asian countries. Treatment options include …

Simple Summary The continuum of care for mCRC might include anti-angiogenic drug as
anti-VEGF/VEGFR moAb and recombinant proteins in combination with fluoropyrimidine …

Aflibercept in combination with 5‑fluorouracil (5‑FU)/irinotecan improves overall survival in
the second‑line therapy of patients with metastatic colorectal cancer (mCRC). In this study …

Background: Metastatic colorectal cancer (mCRC) imposes a heavy tumor burden
worldwide due to limited availability of therapeutic drugs. Aflibercept, a kind of recombinant …

Background Although no data have been reported beyond second-line therapy, aflibercept
is approved in this setting in many countries. We conducted a multicenter study to analyze …

Background Safety and effectiveness of aflibercept with 5‐fluorouracil/levofolinate/irinotecan
have not been reported in Japanese patients with metastatic colorectal cancer (mCRC) in a …

Introduction Aflibercept is a recombinant human fusion protein that acts as a decoy receptor
preventing VEGF-A, VEGF-B, and PlGF from interacting with their receptors. The phase 3 …

For patients with metastatic colorectal cancer (mCRC) that have failed a first-line oxaliplatin-
based regimen, the preferred treatment option is an irinotecan-based regimen. This …